Hjem › Glioblastom › Massachusetts › Boston
Kliniske studier for Glioblastom i Boston, MA
28 studier for Glioblastom søker deltakere på steder i og rundt Boston (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RekruttererFase 2/3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RekruttererFase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RekruttererFase 1/2
- Dana Farber Cancer Institute., Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RekruttererFase 1/2
- Tufts Medical Center, Boston
Anti-GD2 ADC M3554 in Advanced Solid Tumors
RekruttererFase 1
- Dana-Farber Cancer Institute, Boston
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
RekruttererFase 1/2
- Massachusetts General Hospital - Neurology, Boston
- Dana-Farber Cancer Institute - Oncology Department, Boston
Targeted Pediatric High-Grade Glioma Therapy
RekruttererObservasjonsstudie
- Dana-Farber Cancer Institute, Boston
Serial MRI Scans During Radiation Therapy
Rekrutterer
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
RekruttererFase 2
- Susan Chi, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RekruttererFase 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
RekruttererFase 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
RekruttererFase 2
- Dana Farber Cancer Institute, Boston
CARv3-TEAM-E T Cells in Glioblastoma
RekruttererFase 1
- Massachusetts General Hospital Cancer Center, Boston
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
RekruttererFase 2
- Dana-Farber Cancer Institute, Boston
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RekruttererTidlig fase 1Frivillige helsepersonell ønskes velkommen
- Dana-Farber Cancer Institute, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RekruttererFase 2
- Dana-Farber Cancer Institute, Boston
G-CSF After Chemo-radiation in Patients With Glioblastoma
RekruttererFase 2
- Massachusetts General Hospital, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RekruttererFase 1/2
- Dana Farber Cancer Institute, Boston
CUE-102 in Recurrent Glioblastoma
RekruttererFase 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RekruttererFase 1/2
- Dana Farber Cancer Institute, Boston
Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial
RekruttererFase 2
- Brigham and Women's Hospital, Boston
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RekruttererTidlig fase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
Implantable Microdevice In Primary Brain Tumors
RekruttererTidlig fase 1
- Brigham and Women's Hospital, Boston
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
RekruttererObservasjonsstudie
- Massachusetts General Hospital, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
RekruttererObservasjonsstudie
- Massachusetts General Hospital, Boston
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
RekruttererObservasjonsstudie
- Massachusetts General Hospital, Boston
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
RekruttererObservasjonsstudie
- Massachusetts General Hospital, Boston
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
RekruttererObservasjonsstudie
- Massachusetts General Hospital, Boston
Glioblastom-studier i andre byer
- New York City, NY30 studier
- Houston, TX26 studier
- Los Angeles, CA24 studier
- Durham, NC20 studier
- San Francisco, CA17 studier
- Chicago, IL15 studier
- Washington, DC15 studier
- Columbus, OH14 studier
- Miami, FL14 studier
- Rochester, MN13 studier
- Jacksonville, FL13 studier
- Aurora, CO12 studier
Andre studier i Boston
- Brystkreft112 studier
- Ikke-småcellet lungekreft90 studier
- Kreft (alle typer)85 studier
- Metastatisk kreft63 studier
- Kolorektal kreft63 studier
- Lungekreft62 studier
- Eggstokkreft61 studier
- Prostatakreft59 studier
- Depresjon52 studier
- Endometriekreft50 studier
- Hjertesvikt44 studier
- Akut myelogen leukemi44 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.